pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·4h ago·1 min read
save

Atossa Therapeutics CEO Steven Quay likely to become NIAID director

Aug 5, 2026·read at Endpoints ↗Neutral

Steven Quay, founder and CEO of Atossa Therapeutics, is reported to be the likely choice for director of NIH's National Institute of Allergy and Infectious Diseases.

The report notes his background in clinical-stage biotech and his role at Atossa, but provides no further details about the selection process.

If confirmed, Quay would lead the institute that oversees research on infectious diseases, which could have implications for the biotech sector.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Atossa Therapeutics founder to be selected as NIAID director — report”

read at Endpoints ↗
87 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ATOSSA THERAPEUTICS, INC.2

related stories

  • 1h agoFDA approves Takeda's orexin drug for narcolepsyEndpoints
  • 2h agoSenate confirms Erica Schwartz as CDC directorEndpoints
  • 4h agoDemis Hassabis 'leaning into' Isomorphic CEO role amid Alphabet's AI shakeupEndpoints
  • 4h agoIn a first, WuXi AppTec surpasses Lonza’s six-month revenueEndpoints
  • 8h agoArrowhead buys PRV for $215M; Twist hopes to raise $300M in public offeringEndpoints